Pros | ![]() Lower expense ratio. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | ![]() 5Y returns in the bottom 25% of the category. ![]() 3Y returns in the bottom 25% of the category. |
INDMoney rank | 5/8 | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 6 Years | 12 Years | ||
Fund Size | 2441 Cr | 7637 Cr | ||
Min Investment | SIP ₹99 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.52% | 0.91% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | S&P BSE Healthcare PR | S&P BSE Healthcare PR |
No of Holdings | 34 | 39 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.84%) Cipla Ltd (7.6%) Aurobindo Pharma Ltd (7.09%) Divi's Laboratories Ltd (6.53%) Lupin Ltd (6.36%) | Sun Pharmaceuticals Industries Ltd (13.68%) Divi's Laboratories Ltd (9.32%) Lupin Ltd (7.73%) Cipla Ltd (5.9%) Dr Reddy's Laboratories Ltd (5.35%) | ||
No of Sectors | 3 | 1 | ||
Top 3 Sectors | Health (98.63%) Basic Materials (0.86%) Industrial (0.51%) | Health (100%) | ||
Equity % | 99.6% | 98.89% | ||
Debt % | - | - | ||
P/E | 33.85 | 35.31 | ||
P/B | 4.98 | 5.8 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 9.16% | 6.61% | ||
3-Month Return | -6.02% | -7.25% | ||
6-Month Return | -6.42% | -7.74% | ||
1-Year Return | 18.97% | 13.23% | ||
3-Year Return | 19.77% | 19.76% | ||
5-Year Return | 30.98% | 29.58% |
Sharpe | 0.69 | 0.77 | ||
Alpha | -0.39 | 0.8 | ||
Beta | 0.97 | 0.91 | ||
Standard Deviation | 16.65 | 15.64 | ||
Information Ratio | -0.26 | -0.04 |
Description | Mirae Asset Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Vrijesh Kasera | Kinjal Desai,Sailesh Raj Bhan |